Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

The MYC Oncogene Initiates and Maintains Metastasis in Mouse Prostate Cancer Model

By BiotechDaily International staff writers
Posted on 12 Feb 2014
Image: Shown here is a tumor that metastasized from its original site in the prostate to the lung. Researchers were surprised to find the Myc protein in these tumors and, through further experiments, discovered that simply increasing the amount of Myc in the cell was enough to drive metastasis, suggesting a druggable target for metastatic prostate cancer (Photo courtesy of Cold Spring Harbor Laboratory).
Image: Shown here is a tumor that metastasized from its original site in the prostate to the lung. Researchers were surprised to find the Myc protein in these tumors and, through further experiments, discovered that simply increasing the amount of Myc in the cell was enough to drive metastasis, suggesting a druggable target for metastatic prostate cancer (Photo courtesy of Cold Spring Harbor Laboratory).
A mouse metastatic prostate cancer model is expected to enable researchers to better investigate the causes of the disease while at the same time test new therapeutics to treat it.

The RapidCaP genetically engineered mouse (GEM) system was developed by investigators at Cold Spring Harbor Laboratory (NY, USA) who injected viral genes directly into mouse prostate tumors in order to induce them to metastasize.

Examination of these animals and analysis at the molecular level revealed that PI 3-kinase activity, a well-known modulator of prostate cancer, was absent from the RapidCaP metastasized tumors, and that the MYC oncogene was acting as the driving force behind the spread of the tumor. Indeed, they found that prostate tumors could be driven to metastasize simply by increasing the amount of Myc protein.

MYC (v-myc myelocytomatosis viral oncogene homolog protein) is a transcription factor that activates expression of a great number of genes through binding on consensus sequences and recruiting histone acetyltransferases (HATs). By acting as a transcriptional repressor in normal cells, MYC has a direct role in the control of DNA replication. The MYC protein (c-Myc) is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis, and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement, and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias, and lymphomas, including Burkitt lymphoma.

The investigators used RapidCaP to show that Myc both triggered local prostate metastasis and was critical for its maintenance. They further reported in the January 20, 2014, online edition of the journal Cancer Discovery that by treating these animals with the drug JQ1, which reduces the amount of Myc in cells, they could shrink the metastases, suggesting that the switch to Myc was required for maintenance of tumor cells that have metastasized throughout the body.

“The RapidCaP system has revealed a specific role for Myc as a druggable driver of metastasis in prostate cancer,” said senior author Dr. Lloyd Trotman. “So there is hope that our model provides a fast and faithful test-bed for developing new approaches to cure the type of prostate cancer that today is incurable.”

Related Links:

Cold Spring Harbor Laboratory



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.